Cytochrome P450: genotype to phenotype

References

• Abohelaika S, Wynne H, Avery P, et al. (2018). Effect of genetic and patient factors on warfarin pharmacodynamics following warfarin withdrawal: implications for patients undergoing surgery. Thromb Res 171:167–70.
   PubMed Web of Science ®Google Scholar
• Adehin A, Bolaji OO, Maggo S, Kennedy MA. (2017). Relationship between metabolic phenotypes and genotypes of CYP1A2 and CYP2A6 in the Nigerian population. Drug Metab Pers Ther 32:39–47.
   PubMedGoogle Scholar
• Aitken AE, Morgan ET. (2007). Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos 35:1687–93.
   PubMed Web of Science ®Google Scholar
• Annalora AJ, Marcus CB, Iversen PL. (2017). Alternative splicing in the cytochrome P450 superfamily expands protein diversity to augment gene function and redirect human drug metabolism. Drug Metab Dispos 45:375–89.
   PubMed Web of Science ®Google Scholar
• Arafa MH, Atteia HH. (2018). Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6) are associated with long term tramadol treatment-induced oxidative damage and hepatotoxicity. Toxicol Appl Pharmacol 346:37–44.
   PubMed Web of Science ®Google Scholar
• Axelrod J. (1955). The enzymatic demethylation of ephedrine. J Pharmacol Exp Ther 114:430–8.
   PubMed Web of Science ®Google Scholar
• Brodie B, Axelrod J, Cooper JR, et al. (1955). Detoxication of drugs and other foreign compounds by liver microsomes. Science 121:603–4.
   PubMed Web of Science ®Google Scholar
• Burns KE, Shepherd P, Finlay G, et al. (2018). Indirect regulation of CYP2C19 gene expression via DNA methylation. Xenobiotica 48:781–92.
   PubMed Web of Science ®Google Scholar
• Chen Y, Cai S, Wang J, Xu M. (2015). Valproic acid-induced histone acetylation suppresses CYP19 gene expression and inhibits the growth and survival of endometrial stromal cells. Int J Mol Med 36:725–32.
   PubMed Web of Science ®Google Scholar
• Daly AK, King BP. (2003). Pharmacogenetics of oral anticoagulants. Pharmacogenetics 13:247–52.
   PubMedGoogle Scholar
• De Andres F, Sosa-Macias M, Ramos BPL, et al. (2017). CYP450 genotype/phenotype concordance in Mexican Amerindian indigenous populations-where to from here for global precision medicine? OMICS 21:509–19.
   PubMed Web of Science ®Google Scholar
• De Andres F, Teran S, Hernandez F, et al. (2016). To genotype or phenotype for personalized medicine? CYP450 drug metabolising enzyme genotype-phenotype discordance in the Ecuadorian population. OMICS 20:699–710.
   PubMed Web of Science ®Google Scholar
• Dluzen DF, Lazarus P. (2015). MicroRNA regulation of the major drug-metabolising enzymes and related transcription factors. Drug Metab Rev 47:320–34.
   PubMed Web of Science ®Google Scholar
• Donzelli M, Derungs A, Serratore MG, et al. (2014). The basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots. Clin Pharmacokinet 53:271–82.
   PubMed Web of Science ®Google Scholar
• Dorado P, Gonzalez I, Naranjo ME, et al. (2017). Lessons from Cuba for global precision medicine: CYP2D6 genotype is not a robust predictor of CYP2D6 ultrarapid metabolism. OMICS 21:17–26.
   PubMed Web of Science ®Google Scholar
• Drozda K, Pacanowski MA, Grimstein C, Zineh I. (2018). Pharmacogenetic labelling of FDA-approved drugs. A regulatory retrospective. JACC Basic Transl Sci 3:545–9.
   PubMedGoogle Scholar
• Estabrook RW. (1996). Cytochrome P450: from a single protein to a family of proteins – with some personal reflections. In: Ioannides C, ed. Cytochromes P450. Metabolic and toxicological aspects. Boca Raton (FL): CRC Press, 3–28.
   Google Scholar
• Estabrook RW. (2003). A passion for P450 (remembrances of the early history of research on cytochrome P450). Drug Metab Dispos 31:1461–73.
   PubMed Web of Science ®Google Scholar
• FDA. (2019). Table of pharmacogenomics biomarkers in drug labelling. Available from: https://www.fda.gov/media/124784/download [last accessed 18 Jun 2019]; https://www.fda.gov/drugs/science-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling [last accessed 18 Jun 2019].
   Google Scholar
• Floyd JS, Sitlani CM, Avery CL, et al. (2018). Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group. Pharmacogenomics J 18:127–35.
   PubMed Web of Science ®Google Scholar
• Frueh FW, Amur S, Mummaneni P, et al. (2008). Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: prevalence of related drug use. Pharmacotherapy 28:992–8.
   PubMed Web of Science ®Google Scholar
• Frye RF, Schneider VM, Frye CS, Feldman AM. (2002). Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. J Card Fail 8:315–9.
   PubMed Web of Science ®Google Scholar
• Fujita K. (2004). Food-drug interactions via human cytochrome P450 3A (CYP3A). Drug Metabol Drug Interact 20:195–217.
   PubMedGoogle Scholar
• Gaedigk A, Sangkuhl K, Whirl-Carrillo M, et al. (2017). Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med 19:69–76.
   PubMed Web of Science ®Google Scholar
• Gammal RS, Crews KR, Haidar CE, et al. (2016). Pharmacogenetics for safe codeine use in sickle cell disease. Pediatrics 13:e20153479.
   Web of Science ®Google Scholar
• Gallion J, Koire A, Katsonis P, et al. (2017). Predicting phenotype from genotype: improving accuracy through more robust experimental and computational modelling. Hum Mutat 38:569–80.
   PubMed Web of Science ®Google Scholar
• Gao J, Tian X, Zhou J, et al. (2017). From genotype to phenotype: cytochrome P450 2D6-mediated drug clearance in humans. Mol Pharm 14:649–57.
   PubMed Web of Science ®Google Scholar
• Gomes LG, Huang N, Agrawal V, et al. (2009). Extrarenal 21-hydroxylation by CYP2C19 and CYP3A4: effect on 21-hydroxylase deficiency. J Clin Endocrinol Metab 94:89–95.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. (2001). Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 14:611–5.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. (2008). Cytochrome P450 and chemical toxicology. Chem Res Toxicol 21:70–83.
   PubMed Web of Science ®Google Scholar
• Guengerich FP, Munro AW. (2013). Unusual cytochrome p450 enzymes and reactions. J Biol Chem 288:17065–73.
   PubMed Web of Science ®Google Scholar
• Guengerich FP, Waterman MR, Egli M. (2016). Recent structural insights into cytochrome P450 function. Trends Pharmacol Sci 37:625–40.
   PubMed Web of Science ®Google Scholar
• He ZX, Chen XW, Zhou ZW, Zhou SF. (2015). Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine. Drug Metab Rev 47:470–519.
   PubMed Web of Science ®Google Scholar
• Hocum BT, White JR, Jr., Heck JW, et al. (2016). Cytochrome P-450 gene and drug interaction analysis in patients referred for pharmacogenetic testing. Am J Health Syst Pharm 73:61–7.
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. (2005). The human genome project and novel aspects of cytochrome P450 research. Toxicol Appl Pharmacol 207:52–6.
   PubMedGoogle Scholar
• Ioannides C. (1996). Cytochromes P450. Metabolism and toxicological aspects. Boca Raton (FL): CRC Press.
   Google Scholar
• Johansson I, Ingelman-Sundberg M. (2011). Genetic polymorphism and toxicology-with emphasis on cytochrome p450. Toxicol Sci 120:1–13.
   PubMed Web of Science ®Google Scholar
• Karki R, Pandya D, Elston RC, Ferlini C. (2015). Defining “mutation” and “polymorphism” in the era of personal genomics. BMC Med Genomics 8:37.
   PubMed Web of Science ®Google Scholar
• Kim SY, Kang JY, Hartman JH, et al. (2012). Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins. Drug Metab Lett 6:157–64.
   PubMedGoogle Scholar
• Kiss AF, Vasko D, Deri MT, et al. (2018). Combination of CYP2C19 genotype with non-genetic factors evoking phenoconversion improves phenotype prediction. Pharmacol Rep 70:525–32.
   PubMed Web of Science ®Google Scholar
• Kumsta R, Marzi SJ, Viana J, et al. (2016). Severe psychosocial deprivation in early childhood is associated with increased DNA methylation across a region spanning the transcription start site of CYP2E1. Transl Psychiatry 6:e830
   PubMed Web of Science ®Google Scholar
• Lamb DC, Lei L, Warrilow AG, et al. (2009). The first virally encoded cytochrome p450. J Virol 83:8266–9.
   PubMed Web of Science ®Google Scholar
• Lamb DC, Waterman MR. (2013). Unusual properties of the cytochrome P450 superfamily. Philos Trans Royal Soc B 368:20120434.
   PubMed Web of Science ®Google Scholar
• Lee YH, Bae SC. (2017). Association between functional CYP2D6 polymorphisms and susceptibility to autoimmune diseases: a meta-analysis. Immunol Invest 46:109–22.
   PubMed Web of Science ®Google Scholar
• Lewis DFV. (2001). Guide to cytochromes P450. Structure and function. London: Taylor and Francis Group.
   Google Scholar
• Li X, Li W, Liu G, et al. (2015). Association between cigarette smoking and Parkinson’s disease in a meta-analysis. Arch Gerontol Geriatr 61:510–6.
   PubMed Web of Science ®Google Scholar
• Li X, Wang Z, Wang Q, et al. (2019). Clopidogrel-associated genetic variants on inhibition of platelet activation and clinical outcome for acute coronary syndrome patients. Basic Clin Pharmacol Toxicol 124:84–93.
   PubMed Web of Science ®Google Scholar
• Liang Z, Liu J, Huang JX, Zeng X. (2018). Fast screening technology for drug emergency management: predicting suspicious SNPs for ADR with information theory-based models. Comb Chem High Throughput Screen 21:93–9.
   PubMed Web of Science ®Google Scholar
• Lynch T, Price A. (2007). The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician 76:391–6.
   PubMed Web of Science ®Google Scholar
• Manikandan P, Nagini S. (2018). Cytochrome P450 structure, function and clinical significance: a review. Curr Drug Targets 19:38–54.
   PubMed Web of Science ®Google Scholar
• McGraw J, Gerhardt A, Morris TC. (2018). Opportunities and obstacles in genotypic prediction of cytochrome P450 phenotypes. Expert Opin Drug Metab Toxicol 14:659–61.
   PubMed Web of Science ®Google Scholar
• McGraw J, Waller D. (2012). Cytochrome P450 variations in different ethnic populations. Expert Opin Drug Metab Toxicol 8:371–82.
   PubMed Web of Science ®Google Scholar
• Monte AA, Heard KJ, Vasiliou V. (2012). Prediction of drug response and safety in clinical practice. J Med Toxicol 8:43–51.
   PubMedGoogle Scholar
• Moretti ME, Lato DF, Berger H, et al. (2018). A cost-effectiveness analysis of maternal CYP2D6 genetics testing to guide treatment for post-partum pain and avert infant adverse events. Pharmacogenomics 18:391–7.
   Web of Science ®Google Scholar
• Naranjo ME, de Andres F, Delgado A, et al. (2016). High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in world-wide population studies. Pharmacogenomics J 16:485–90.
   PubMed Web of Science ®Google Scholar
• Nebert DW, Wikvall K, Miller WL. (2013). Human cytochromes P450 in health and disease. Philos Trans R Soc Lond B Biol Sci 368:20120431.
   PubMed Web of Science ®Google Scholar
• Nelson D. (2003). Cytochrome P450 in humans. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3500189/
   Google Scholar
• Nelson D. (2009). The cytochrome P450 homepage. Hum Genomics 4:59–65.
   PubMedGoogle Scholar
• Nelson DR, Zeldin DC, Hoffman SMG, et al. (2004). Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative splice-variants. Pharmacogenetics 14:1–18.
   PubMedGoogle Scholar
• Omura T, Sato R. (1964a). The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370–8.
   PubMed Web of Science ®Google Scholar
• Omura T, Sato R. (1964b). The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification and properties. J Biol Chem 239:2378–85.
   Web of Science ®Google Scholar
• Painter JN, Nyholt DR, Krause L, et al. (2014). Common variants in the CYP2C19 gene are associated with susceptibility to endometriosis. Fertil Steril 102:496–502.
   PubMed Web of Science ®Google Scholar
• Pouchieu C, Piel C, Carles C, et al. (2018). Pesticide use in agriculture and Parkinson’s disease in the AGRICAN cohort study. Int J Epidemiol 47:299–310.
   PubMed Web of Science ®Google Scholar
• Preissner SC, Hoffmann MF, Preissner R, et al. (2013). polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. PLoS One 8:e82562.
   PubMed Web of Science ®Google Scholar
• Preissner S, Kroll K, Dunkel M, et al. (2010). SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res 38:D237–43.
   PubMed Web of Science ®Google Scholar
• Raman G, Chang LKW, Gaylor JM, et al. (2012). Update on mapping the landscape for genetic tests for non-cancer disease/conditions. Appendix C. Pharmacogenomic biomarkers in drug labels from the FDA web site. Rockville (MD): Agency for Healthcare Research and Quality (US), C1–3.
   Google Scholar
• Ravindranath V, Strobel HW. (2013). Cytochrome P450-mediated metabolism in brain: functional roles and their implications. Expert Opin Drug Metab Toxicol 9:551–8.
   PubMed Web of Science ®Google Scholar
• Rieger JK, Reutter S, Hofmann U, et al. (2015). Inflammation-associated microRNA-130b down-regulates cytochrome P450 activities and directly targets CYP2C9. Drug Metab Dispos 43:884–8.
   PubMed Web of Science ®Google Scholar
• Rogers HL, Pacanowski M. (2014). 3: Pharmacogenomic information in drug labelling. In: Murray MF, Babyatsky MW, Giovanni MA, Alkuraya FS, Stewart DR, eds. Clinical genomics: practical applications in adult patient care. New York: McGraw-Hill, 7–11.
   Google Scholar
• Seripa D, Panza F, Daragjati J, et al. (2015). Measuring pharmacogenetics in special groups: geriatrics. Expert Opin Drug Metab Toxicol 11:1073–88.
   PubMed Web of Science ®Google Scholar
• Shah RR, Smith RL. (2015). Addressing phenoconversion: the Achilles heel of personalised medicine. Br J Clin Pharmacol 79:222–40.
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, et al. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–23.
   PubMed Web of Science ®Google Scholar
• Sim SC, Risinger C, Dahl ML, et al. (2006). A common novel CYP2C19 gene variant causes ultra-rapid drug metabolism relevant for the drug response to proton pump inhibitors and depressants. Clin Pharmacol Ther 79:103–13.
   PubMed Web of Science ®Google Scholar
• Spinello A, Martini S, Berti F, et al. (2019). Rational design of allosteric modulators of the aromatase enzyme: an unprecedented therapeutic strategy to fight breast cancer. Eur J Med Chem 168:253–62.
   PubMed Web of Science ®Google Scholar
• Spokoyny I, Barazangi N, Jaramillo V, et al. (2014). Reduced clopidogrel metabolism in a multi-ethnic population: prevalence and rates of recurrent cerebrovascular events. J Stroke Cerebrovas Dis 23:694–8.
   PubMed Web of Science ®Google Scholar
• Tang X, Chen S. (2015). Epigenetic regulation of cytochrome P450 enzymes and clinical implications. Curr Drug Metab 16:86–96.
   PubMed Web of Science ®Google Scholar
• Tebbens JD, Azar M, Friedmann E, et al. (2018). Mathematical models in description of PXR-regulated cytochrome P450 enzyme induction. Int J Mol Sci 19:1785.
   PubMed Web of Science ®Google Scholar
• Temesvari M, Kobori L, Paulik J, et al. (2012). Estimation of drug-metabolising capacity by cytochrome P450 genotyping and expression. J Pharmacol Exp Ther 341:294–305.
   PubMed Web of Science ®Google Scholar
• Tiili EM, Antikainen MS, Mitiushkina NV, et al. (2015). Effect of genotype and methylation of CYP2D6 on smoking behaviour. Pharmacogenet Genom 25:531–40.
   PubMed Web of Science ®Google Scholar
• Tobias JD, Green TP, Cote CJ. (2016). Codeine: time to say ‘No’. Pediatrics 138:e20162396.
   PubMed Web of Science ®Google Scholar
• Tracy TS, Chaudhry AS, Prasad B, et al. (2016). Interindividual variability in cytochrome P450-mediated drug metabolism. Drug Metab Dispos 44:343–51.
   PubMed Web of Science ®Google Scholar
• Tracy TS, Marra C, Wrighton SA, et al. (1997). Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation. Eur J Clin Pharmacol 52:293–8.
   PubMed Web of Science ®Google Scholar
• Tutton R. (2014). Pharmacogenomic biomarkers in drug labels: what do they tell us?. Pharmacogenomics 15:297–304.
   PubMed Web of Science ®Google Scholar
• Uppugunduri CR, Daali Y, Desmeules J, et al. (2012). Transcriptional regulation of CYP2C19 and its role in altered enzyme activity. Curr Drug Metab 13:1196–204.
   PubMed Web of Science ®Google Scholar
• Ur Rasheed MS, Mishra AK, Singh MP. (2017). Cytochrome P450 2D6 and Parkinson’s disease: polymorphism, Metabolic Role, Risk and Protection. Neurochem Res 42:3353–61.
   PubMed Web of Science ®Google Scholar
• Vachirayonstien T, Yan B. (2016). MicroRNA-30c-1-3p is a silencer of the pregnane X receptor by targeting the 3′-untranslated region and alters the expression of its target gene cytochrome P450 3A4. Biochim Biophys Acta 1859:1238–44.
   PubMed Web of Science ®Google Scholar
• Vassy JL, Stone A, Callaghan JT, et al. (2019). Pharmacogenetic testing in the Veterans Health Administration (VHA): policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee. Genet Med 21:382–90.
   PubMed Web of Science ®Google Scholar
• Vivot A, Boutron I, Ravaud P, Porcher R. (2015). Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs. Genet Med 17:733–8.
   PubMed Web of Science ®Google Scholar
• Wang D, Poi MJ, Sun X, et al. (2014). Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with 2 regulatory variants modulate CYP2D6 activity. Hum Mol Genet 23:268–78.
   PubMed Web of Science ®Google Scholar
• Wendt FR, Sajantila A, Budowle B. (2018). Predicted activity of UGT2B7, ABCB1, OPRM1, and COMT using full-gene haplotypes and their association with the CYP2D6-inferred metabolizer phenotype. Forensic Sci Int Gen 33:48–58.
   PubMed Web of Science ®Google Scholar
• Yamazaki H. (2014). Fifty years of cytochrome P450 research. Tokyo: Springer.
   Google Scholar
• Zeng L, Chen Y, Wang Y, et al. (2017). MicroRNA has-miR-370-3p suppresses the expression and induction of CYP2D6 by facilitating mRNA degradation. Biochem Pharmacol 140:139–49.
   PubMed Web of Science ®Google Scholar
• Zhang GE, Nebert DW. (2017). Personalized medicine: genetic risk prediction of drug response. Pharmacol Ther 175:75–90.
   PubMed Web of Science ®Google Scholar
• Zhou S. (2016). Cytochrome P450 2D6: structure, function, regulation and polymorphism. Boca Raton (FL): CRC Press.
   Google Scholar
• Zhou SF, Liu JP, Chowbay B. (2009). Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41:89–295.
   PubMed Web of Science ®Google Scholar